Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors

Annals of Oncology

Volumn 17, Issue 5, 2006, Pages 866-873

  Richly, H ^a   Henning, B F ^b   Kupsch, P ^a   Passarge, K ^a   Grubert, M ^a   Hilger, R A ^a   Christensen, O ^c   Brendel, E ^c   Schwartz, B ^d   Ludwig, M ^e   Flashar, C ^b   Voigtmann, R ^b   Scheulen, M E ^a   Seeber, S ^a   Strumberg, Dirk ^a,b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c BAYER PHARMA AG   (Germany)

^d BAYER CORPORATION   (United States)

^e MARCO Institute for Clinical Research and Statistics   (Germany)

Author keywords

BAY 43 9006; Doxorubicin; Phase I; Raf kinase; Sorafenib

Indexed keywords

AMYLASE; DOXORUBICIN; SORAFENIB; TRIACYLGLYCEROL LIPASE;

ADULT; AGED; ALOPECIA; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DESQUAMATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; NAUSEA AND VOMITING; NEUTROPENIA; PHARYNGITIS; PHASE 1 CLINICAL TRIAL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; SOLID TUMOR; STOMATITIS; THROMBOCYTOPENIA;

EID: 33646204716     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl017     Document Type: Article

References (46)

1. Strumberg D, Richly H, Hilger RA et al. Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors. J Clin Oncol 2005; 23: 965-972.
2. Awada A, Hendlisz A, Gil T et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005; 92: 1855-1861.
3. Clark JW, Eder JP, Ryan D et al. The safety and pharmacokinetics of the multitargeted tyrosine kinase inhibitor (including Raf kinase and VEGF kinase), BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 2005; 11: 5472-5480.
4. Moore MJ, Hirte HW, Siu L et al. Phase I study to determine the safety and pharmacokinetics of BAY 43-9006 in patients with advanced, refractory solid tumours. Ann Oncol 2005; 16: 1688-1694.
5. Abou-Alfa GK, Schwartz L, Ricci S et al. Phase II study of BAY 43-9006 in patients with advanced hepatocellular carcinoma (HCC). Eur J Cancer 2004; 2: 16 (Abstr 42).
6. Escudier B, Szczylik C, Eisen T et al. Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 2005; 23: 1093s.
7. Ratain MJ, Eisen T, Stadler WM et al. Final findings from a Phase II, placebo controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 2005; 23: 388s.
8. Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral anti-tumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-7109.
9. Alavi A, Hood JD, Frausto R et al. Role of Raf in vascular protection from distinct apoptotic stimuli. Science 2003; 301: 94-96.
10. Chen J, Fujii K, Zhang L et al. Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism. Proc Natl Acad Sci USA 2001; 98: 7783-7788.
11. Troppmair J, Rapp UR. Raf and the road to cell survival: A tale of bad spells, ring bearers and detours. Biochem Pharmacol 2003; 66: 1341-1345.
12. Wang HG, Rapp UR, Reed JC. Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell 1996; 87: 629-638.
13. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol 1992; 3: 65-71.
14. Vincent P, Zhang X, Chen C et al. Preclinical chemotherapy with the Raf kinase inhibitor BAY 43-9006 in combination with gefitinib, venorelbine, gemcitabine or doxorubicin. Proc Am Assoc Cancer Res 2003; 44 (2nd edn): Abstr 719.
15. Chapner BA, Longo DL. Cancer Chemotherapy and Biotherapy. 2nd Edition. Philadelphia: Lippincott-Raven 1996, 1996.
16. Blalock WL, Pearce M, Steelman LS et al. A conditionally-active form of MEK1 results in autocrine tranformation of human and mouse hematopoietic cells. Oncogene 2000; 19: 526-536.
17. Cornwell MM, Smith DE. A signal transduction pathway for activation of the mdr1 promoter involves the proto-oncogene c-raf kinase. J Biol Chem 1993; 268: 15347-15350.
18. Hoyle PE, Moye PW, Steelman LS et al. Differential abilities of the Raf family of protein kinases to abrogate cytokine dependency and prevent apoptosis in murine hematopoietic cells by a MEK1-dependent mechanism. Leukemia 2000; 14: 642-656.
19. Kim SH, Lee SH, Kwak NH et al. Effect of the activated Raf protein kinase on the human multidrug resistance 1 (MDR1) gene promoter. Cancer Lett 1996; 98: 199-205.
20. Lau QC, Brusselbach S, Muller R. Abrogation of c-Raf expression induces apoptosis in tumor cells. Oncogene 1998; 16: 1899-1902.
21. McCubrey JA, Steelman LS, Hoyle PE et al. Differential abilities of activated Raf oncoproteins to abrogate cytokine dependency, prevent apoptosis and induce autocrine growth factor synthesis in human hematopoietic cells. Leukemia 1998; 12: 1903-1929.
22. Weinstein-Oppenheimer CR, Henriquez-Roldan CF, Davis JM et al. Role of the Raf signal transduction cascade in the in vitro resistance to the anticancer drug doxorubicin. Clin Cancer Res 2001; 7: 2898-2907.
23. Zhong J, Troppmair J, Rapp UR. Independent control of cell Osurvival by Raf-1 and Bcl-2 at the mitochondria. Oncogene 2001; 20: 4807-4816.
24. Doxorubicin Prescribing Information Update 2003. http://www.fda.gov/ medwatch/SAFETY/2003/03May_PI/Doxorubicin_PI.pdf (Date last accessed: February 16, 2006)
25. McCubrey JA, May WS, Duronio V, Mufson A. Serine/threonine phosphorylation in cytokine signal transduction. Leukemia 2000; 14: 9-21.
26. McCubrey JA, Lee JT, Steelman LS et al. Interactions between the PI3K and Raf signaling pathways can result in the transformation of hematopoietic cells. Cancer Detect Prev 2001; 25: 375-393.
27. Weinstein-Oppenheimer C, Steelman LS, Algate PA et al. Effects of deregulated Raf activation on integrin, cytokine-receptor expression and the induction of apoptosis in hematopoietic cells. Leukemia 2000; 14: 1921-1938.
28. Blalock WL, Moye PW, Chang F et al. Combined effects of aberrant MEK1 activity and BCL2 overexpression on relieving the cytokine dependency of human and murine hematopoietic cells. Leukemia 2000; 14: 1080-1096.
29. Moye PW, Blalock WL, Hoyle PE et al. Synergy between Raf and BCL2 in abrogating the cytokine dependency of hematopoietic cells. Leukemia 2000; 14: 1060-1079.
30. Chen W, Yu YL, Lee SF et al. CREB is one component of the binding complex of the Ces-2/E2A-HLF binding element and is an integral part of the interleukin-3 survival signal. Mol Cell Biol 2001; 21: 4636-4646.
31. Pugazhenthi S, Miller E, Sable C et al. Insulin-like growth factor-I induces bcl-2 promoter through the transcription factor cAMP-response element-binding protein. J Biol Chem 1999; 274: 27529-27535. promoter through the transcription factor cAMP-response element-binding protein. J Biol Chem 1999; 274: 27529-27535.
32. Pugazhenthi S, Nesterova A, Sable C et al. Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. J Biol Chem 2000; 275: 10761-10766.
33. Wilson BE, Mochon E, Boxer LM. Induction of bcl-2 expression by phosphorylated CREB proteins during B-cell activation and rescue from apoptosis. Mol Cell Biol 1996; 16: 5546-5556.
34. Deng X, Ruvolo P, Carr B, May WS, Jr. Survival function of ERK1/2 as IL-3-activated, staurosporine-resistant Bcl2 kinases. Proc Natl Acad Sci USA 2000; 97: 1578-1583.
35. Davis JM, Navolanic PM, Weinstein-Oppenheimer CR et al. Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance. Clin Cancer Res 2003; 9: 1161-1170.
36. Gokhale PC, Zhang C, Newsome JT et al. Pharmacokinetics, toxicity, and efficacy of ends-modified raf antisense oligodeoxyribonucleotide encapsulated in a novel cationic liposome. Clin Cancer Res 2002; 8: 3611-3621.
37. Mewani RR, Tang W, Rahman A et al. Enhanced therapeutic effects of doxorubicin and paclitaxel in combination with liposome-entrapped ends-modified raf antisense oligonucleotide against human prostate, lung and breast tumor models. Int J Oncol 2004; 24: 1181-1188.
38. Yeo W, Zee B, Leung WT et al. A Phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil for inoperable hepatocellular carcinoma. J Clin Oncol 2004; 22 (Abstr 4026).
39. Giambartolomei S, Covone F, Levrero M, Balsano C. Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the Hepatitis C Virus (HCV) core protein. Oncogene 2001; 20: 2606-2610.
40. Huynh H, Nguyen TT, Chow KH et al. Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: Its role in tumor progression and apoptosis. BMC Gastroenterol 2003; 3: 19.
41. Yoshiji H, Kuriyama S, Yoshii J et al. Involvement of the vascular endothelial growth factor receptor-1 in murine hepatocellular carcinoma development. J Hepatol 2004; 41: 97-103.
42. Siu LL, Awada A, Takimoto CH et al. A phase I/II trial of BAY 43-9006 and gemcitabine in advanced solid tumors and in advanced pancreatic cancer. Proc Am Soc Clin Oncol 2004; 23: 209 (Abstr 3059).
43. Flaherty KT, Brose M, Schuchter L et al. Phase I/II trial of BAY 43-9006, carboplatin and paclitaxel demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma. Proc Am Soc Clin Oncol 2004; 23: 708.
44. Flaherty KT, Lee RJ, Humphries R et al. Phase I trial of BAY 43-9006 in combination with carboplatin (C) and paclitaxel (P). Proc Am Soc Clin Oncol 2003; 22: 710.
45. Hodi FS, Soiffer RJ, Clark J et al. Phase II study of paclitaxel and carboplatin for malignant melanoma. Am J Clin Oncol 2002; 25: 283-286.
46. Zimpfer-Rechner C, Hofmann U, Figl R et al. Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: A multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG). Melanoma Res 2003; 13: 531-536.